DexCom, Inc. (DXCM)
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom NASDAQ: DXCM used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement.
Here's Why DexCom (DXCM) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom, Inc. (DXCM) Analyst/Investor Day Transcript
DexCom, Inc. (DXCM) Analyst/Investor Day Transcript
3 Reasons Analysts Love DexCom
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes. With about 40 million people in the United States suffering from diabetes, and incidents of type 2 diabetes rising across multiple demographics, this core function of this class of medicines is still just as relevant as it was when these drugs first became available.
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise
DXCM stock jumps on Q1 beat as revenues rise 15% and margins expand, with strong CGM demand and raised profitability outlook boosting momentum.
DexCom, Inc. (DXCM) Q1 2026 Earnings Call Transcript
DexCom, Inc. (DXCM) Q1 2026 Earnings Call Transcript
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.32 per share a year ago.
DXCM or MASI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either DexCom (DXCM) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
Why DexCom (DXCM) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will DXCM's G7 Uptake Continue to Drive Top-line Growth in Q1?
DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins.
